134 related articles for article (PubMed ID: 9617622)
1. [Prognostic significance of clinical stage including extent of disease (EOD) in prostate cancer].
Fujinami K; Kondo I; Miura T; Harada M; Uemura H; Hosaka M; Kawasaki C
Hinyokika Kiyo; 1998 Apr; 44(4):259-63. PubMed ID: 9617622
[TBL] [Abstract][Full Text] [Related]
2. [Clinical analysis of 169 patients with prostate cancer].
Okaneya T; Mizusawa H; Yoneyama T; Taguchi I; Komiyama I; Kawakami M; Hosaka K; Tsuruta T; Murata Y; Komatsu H; Misawa K; Kiyokawa H
Hinyokika Kiyo; 1996 Aug; 42(8):563-7. PubMed ID: 8889563
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of prostate cancer--statistical analysis in the last 10 years].
Yamamoto N; Shimabukuro T; Matsuyama H; Yoshihiro S; Mitsui H; Sakatoku J
Hinyokika Kiyo; 1991 Jul; 37(7):705-10. PubMed ID: 1927770
[TBL] [Abstract][Full Text] [Related]
4. [Combination therapy with estrogen and UFT in newly diagnosed prostatic cancer (poorly differentiated, stage D2)].
Kondo I; Miura T; Fujii H; Harada M; Fukushima S; Kubota Y; Hosaka M
Hinyokika Kiyo; 1996 Mar; 42(3):201-6. PubMed ID: 8619389
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between histologic grading and prognosis of prostatic cancer--comparing the grading system of the Japanese general rules of prostatic cancer with Gleason's grading].
Hioki T; Sugimura Y; Sakurai M; Hayashi N; Tochigi H; Kawamura J; Yatani R
Hinyokika Kiyo; 1990 Aug; 36(8):921-6. PubMed ID: 2239593
[TBL] [Abstract][Full Text] [Related]
6. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of prostate cancer: statistical analysis of 107 cases in the past 12 years].
Umeda Y; Hayashi N; Ogawa K; Kuromatsu I; Franco OE; Su J; Yamakawa K; Arima K; Yanagawa M; Kawamura J
Hinyokika Kiyo; 2000 Dec; 46(12):873-8. PubMed ID: 11211803
[TBL] [Abstract][Full Text] [Related]
9. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study on adenocarcinoma of the prostate].
Yamamoto A; Yuasa M; Imagawa A; Kagawa S; Kurokawa K
Hinyokika Kiyo; 1987 Dec; 33(12):2050-4. PubMed ID: 3448932
[TBL] [Abstract][Full Text] [Related]
11. [Effect of tegafur administration combined with hormonal therapy in patients with newly diagnosed stage D prostatic cancer].
Kobayashi N; Yoshida K; Takahashi T; Saitoh H; Tari K; Satake I; Kojima S; Tsujii T; Negishi T; Horiuchi S
Hinyokika Kiyo; 1990 Jul; 36(7):793-800. PubMed ID: 2239576
[TBL] [Abstract][Full Text] [Related]
12. [Clinical analysis of 683 prostatic cancer patients in the Tokai Urological Cancer Registry].
Obata JK; Kuriyama M; Fujita K; Sakai S; Okishio N; Sakagami H; Higashino I; Miyake K
Hinyokika Kiyo; 1996 Jul; 42(7):503-7. PubMed ID: 8809558
[TBL] [Abstract][Full Text] [Related]
13. [Clinical studies on recurrent prostatic cancer].
Suzuki K; Nakamura T; Kato N; Suzuki T; Imai K; Yamanaka H
Hinyokika Kiyo; 1991 Jun; 37(6):595-600. PubMed ID: 1892007
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of incidental prostatic carcinoma].
Maeda O; Saiki S; Kinouchi T; Kuroda M; Miki T; Usami M; Kotake T
Hinyokika Kiyo; 1991 Feb; 37(2):135-9. PubMed ID: 2048491
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study of total prostatectomy for prostatic cancer].
Fujii A; Gohji K; Morisue K; Maruyama S; Kizaki T; Oka N
Hinyokika Kiyo; 1994 Feb; 40(2):111-7. PubMed ID: 8128919
[TBL] [Abstract][Full Text] [Related]
16. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
17. [Prognosis of prostate cancer with elevated prostatic acid phosphatase].
Saito T; Kitamura Y; Komatsubara S
Hinyokika Kiyo; 2006 Mar; 52(3):177-80. PubMed ID: 16617869
[TBL] [Abstract][Full Text] [Related]
18. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
Shimbo M; Suzuki H; Kamiya N; Imamoto T; Komiya A; Ueda T; Watanabe M; Shiraishi T; Ichikawa T
Eur Urol; 2005 Apr; 47(4):557-63. PubMed ID: 15774258
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of pulmonary metastases in stage D2 prostate cancer patients.
Nakamachi H; Suzuki H; Akakura K; Imamoto T; Ueda T; Ishihara M; Furuya Y; Ichikawa T; Igarashi T; Ito H
Prostate Cancer Prostatic Dis; 2002; 5(2):159-63. PubMed ID: 12497007
[TBL] [Abstract][Full Text] [Related]
20. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
Martinez A; Gonzalez J; Spencer W; Gustafson G; Kestin L; Kearney D; Vicini FA
J Urol; 2003 Mar; 169(3):974-9; discussion 979-80. PubMed ID: 12576825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
